Can a gut antibiotic ease Chemo's stomach woes?

NCT ID NCT04249622

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested the antibiotic rifaximin (Xifaxan) to see if it could reduce stomach issues like bloating, pain, and diarrhea in people with early-stage HER2-positive breast cancer receiving pertuzumab-based chemotherapy. The trial planned to enroll 20 patients but was terminated early. The goal was to help patients complete their cancer treatment without delays or dose reductions due to side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
rifaximin (Xifaxan)
What this could lead to
If it works, this could offer a way to manage severe stomach side effects from breast cancer treatment, helping patients stay on their chemotherapy schedule.
What could go wrong
This was a small, early-phase trial that was terminated before completion, so results are limited. It is not a treatment for cancer itself, only for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.